Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [H1792_RNA-seq]

ABSTRACT: SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [H1792_RNA-seq]

PROVIDER: PRJNA1124132 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29422617_1.fastq.gz	Fastqsanger.gz
	SRR29422617_2.fastq.gz	Fastqsanger.gz
	SRR29422618_1.fastq.gz	Fastqsanger.gz
	SRR29422618_2.fastq.gz	Fastqsanger.gz
	SRR29422619_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner

Project description:Genomic studies have identified frequent alterations in components of the SWI/SNF (SWItch/Sucrose Non- Fermenting) chromatin remodeling complex including SMARCA4 and ARID1A. Recent independent clinical studies have shown that SMARCA4 mutant lung cancer patients have very poor response to immunotherapy but the mechanism is unknown. Here we showed that SMARCA4 deficiency caused resistance to anti-PD1 immunotherapy and decreased CD4+ T cell and conventional class I dendritic cells (“cDC1s”) percentage in tumor microenvironment (TME) with mouse models. SMARCA4 loss in tumor cells prevented STING pathway sensing cytosolic DNA and cGAMP to reduce type I IFN and inflammatory cytokine gene expression. Importantly, SMARCA4 degradation induced a profound reprograming of the enhancer landscape with marked loss of chromatin accessibility at enhancers of genes involved in type I IFN and inflammatory cytokine, which is associated with nuclear factor NF-κB pathway. Our finding reveals that SMARCA4 loss can have a critical immune modulatory impact in cancer cell intrinsic fashion and suggest that manipulation of SMARCA4 in tumor cells can improve cancer immunotherapy.

2025-02-26 | GSE269551 | GEO

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner II

2025-02-26 | GSE269686 | GEO

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [CUT&RUN]

2025-02-26 | GSE278869 | GEO

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [RNA-Seq]

2025-02-26 | GSE278868 | GEO

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [H1792_RNA-seq]

2025-02-26 | GSE269930 | GEO

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [ChIP-seq3]

2025-02-26 | GSE288649 | GEO

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner

Project description:SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner

| PRJNA1122500 | ENA

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [H1975 and HCC44]

2025-02-26 | GSE269618 | GEO

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner II

Project description:SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner II

| PRJNA1123224 | ENA

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [RNA-Seq]

Project description:SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [RNA-Seq]

| PRJNA1169331 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data